Two companies importing the same category of medicine can end up owing wildly different amounts at the border, and the difference isn’t luck. A pharmaceutical tariff signed in April carved out two separate escape routes from its steepest rate, and drug manufacturers have spent the months since deciding which one, if either, to take. One path cuts the bill by four-fifths. The other erases it, for now, for companies that agree to something the government cares about just as much as where a drug is made.
The Same Proclamation, Two Off-Ramps
The underlying policy, an April 2, 2026 proclamation on patented pharmaceutical imports, sets a 100 percent tariff on patented, brand-name pharmaceuticals and their ingredients as the default rate. But the same proclamation lays out two ways around it. A manufacturer with a production onshoring plan approved by the Commerce Department pays 20 percent instead of 100. And a manufacturer that both qualifies for that onshoring treatment and has separately signed a most-favored-nation pricing agreement with the Department of Health and Human Services pays zero percent, at least through a fixed date years away.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
What Counts as an Approved Onshoring Plan
Both discounts are written directly into the proclamation’s own operative clauses, not implied or inferred from commentary about it, and the 20 percent rate isn’t automatic just because a company says it plans to build in the United States eventually. The proclamation directs the Commerce Department to set formal criteria for these onshoring plans, publish them, and then approve, monitor and enforce each one individually, including requiring periodic progress reports that can be independently audited by an outside firm. If Commerce later determines a company engaged in fraud or otherwise misled the government about its onshoring commitments, the proclamation allows the tariff to be reimposed both prospectively and retroactively. In other words, the discount is conditioned on real, tracked construction and production commitments, verified over time, not a press release announcing an intention to build someday.
The Deeper Discount: A Pricing Deal With HHS
The zero percent rate requires something else entirely: a signed most-favored-nation pricing agreement with the Department of Health and Human Services, on top of qualifying for the onshoring treatment. These MFN agreements commit a manufacturer to pricing its drugs for American patients in line with the lower prices those same drugs sell for in other wealthy countries. According to the White House’s own account of the program, published August 31, 2026, the administration had by that date reached MFN pricing agreements with 26 pharmaceutical manufacturers, covering an estimated 89 percent of the branded drug market, including companies such as Pfizer, Eli Lilly, Novo Nordisk, Merck and Johnson & Johnson. Nine of those 26 deals were announced that same week, with the companies collectively committing more than $19.6 billion toward U.S. manufacturing investment and donating raw pharmaceutical ingredients to the government’s strategic stockpile.
Zero Percent Has an Expiration Date
The zero-tariff treatment isn’t permanent. The proclamation sets it to run only until January 20, 2029, after which those companies would presumably fall back to whatever rate structure is in place at that point, unless the terms are extended or renegotiated before then. That’s a detail easy to miss in coverage that focuses on the headline number, but it matters for understanding this as a multi-year bridge tied to a specific pricing commitment, not a permanent exemption baked into the tariff code. It also means a company’s zero rate today doesn’t guarantee zero three years from now; nothing in the proclamation’s text obligates the government to renew the arrangement once the January 2029 date arrives.
Why the Administration Built the Ladder This Way
The tariff and the pricing deals aren’t separate initiatives running in parallel; the proclamation treats them as connected levers. The stated goal, laid out in the White House’s own framing of the underlying national-security investigation, is to push more patented drug production back into the United States while also pressuring manufacturers to stop charging Americans more than they charge in other developed countries for the same medicines. A flat 100 percent tariff with no off-ramp would raise costs on imported drugs without necessarily changing where they’re made or how they’re priced here; the tiered structure is designed to reward the specific behaviors, onshoring and MFN pricing, that the administration says it wants more of.
What This Doesn’t Guarantee at the Pharmacy
None of this legally requires a company that wins the discount to lower a specific drug’s price at the counter; the MFN agreements set pricing commitments on the products named in each deal, and separate market forces, insurance formularies and pharmacy benefit manager contracts still shape what a patient actually pays out of pocket. The clearest, most durable fact here is the one written into the proclamation and repeated in the administration’s own updates: an approved onshoring plan buys a company an 80 percent cut in the tariff rate, and a paired MFN pricing deal buys it a clean exemption through January 20, 2029.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
